The forecasted sales for Genito Urinary System and Sex Hormones in Canada depict a downward trend from 2024 to 2028. Sales declined from 3.7% in 2024 to 2.9% of Total Sales in 2028. Year-on-year variations show a consistent decrease, averaging a CAGR of -5.8% over the five-year forecast period. This reflects a projected reduction in market demand or possible competitive factors influencing sales.

Future trends to watch for:

Potential impact of newer therapies or innovations on market recovery.
Regulatory changes that might affect market dynamics or product approval processes.
Prescription patterns and demographic shifts influencing demand for these medications.